Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR-T Treated T-cell Lymphoid Malignancies.

Blood cancer discovery·2026
Same author

Dietary Bile Acids Improve Serum Antioxidant Status and Modulate Fecal Microbiota in Culled Ewes.

Animals : an open access journal from MDPI·2026
Same author

Highly Cα-regio-, enantio- and diastereoselective Mukaiyama-type annulation of siloxyfurans: stereodivergent synthesis of multi-stereogenic tricyclic γ-lactones.

Chemical science·2026
Same author

Association between blood metabolites and chronic respiratory diseases: A Mendelian randomization study.

Medicine·2026
Same author

Single-Cell Analysis of Zinc Ions During Electrical Stimulation-Induced Pyroptosis by DNAzyme-Functionalized Glass Nanopipettes.

Analytical chemistry·2026
Same author

KIAA1429 promotes clear cell renal cell carcinoma progression by regulating MYC mRNA stability.

iScience·2026

Related Experiment Video

Updated: Jun 9, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K

Pseudoprogression in CAR-T cell therapy for solid tumor: Case report.

Xuan Zhao1,2, Yanfen Liu1,2, Guohui Qin1,2

  • 1Biotherapy Center & Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Frontiers in Immunology
|January 23, 2025
PubMed
Summary
This summary is machine-generated.

This case study describes pseudoprogression, a temporary worsening of tumors, in an elderly patient with advanced gastric cancer treated with chimeric antigen receptor (CAR)-T cell therapy. This phenomenon, characterized by initial tumor enlargement followed by shrinkage, offers insights into CAR-T cell therapy.

Keywords:
CAR-T cell therapycellular immunotherapyevaluation of therapeutic efficacygastric cancerpseudoprogression

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

795

Related Experiment Videos

Last Updated: Jun 9, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

795

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • Advanced gastric cancer presents significant treatment challenges.
  • Chimeric antigen receptor (CAR)-T cell therapy is an emerging immunotherapy for various cancers.

Observation:

  • An elderly patient with advanced gastric cancer received CAR-T cell therapy.
  • Computed tomography scans revealed initial enlargement of hepatic metastases one month post-infusion.

Findings:

  • The hepatic metastases subsequently demonstrated shrinkage in the following month.
  • A comprehensive evaluation, including imaging, pathology, and clinical symptoms, confirmed pseudoprogression.
  • This represents the first reported case of pseudoprogression following CAR-T cell therapy in gastric cancer.

Implications:

  • This case highlights the importance of recognizing pseudoprogression as a potential response pattern in CAR-T cell therapy.
  • Accurate diagnosis of pseudoprogression is crucial to avoid misinterpreting tumor growth as treatment failure.
  • Understanding pseudoprogression can refine clinical trial design and patient management strategies for CAR-T cell therapy in gastric cancer.